[Management of ablative therapies in prostate cancer].

OBJECTIVES: To describe the specific modalities of ablative therapies management in prostate cancer.

MATERIALS AND METHODS: A review of the scientific literature was performed in Medline database (https://www.ncbi.nlm.nih.gov) and Embase (https://www.embase.com) using different associations of keywords. Publications obtained were selected based on methodology, language and relevance. After selection, 61 articles were analysed.

RESULTS: Development of innovations such as ablative therapies in prostate cancer induces specific modalities in their management, during pre-, per- and post-procedure. More than for classical and well-known treatments, the decision to propose an ablative therapy requires analysis and consensus of medical staff and patient's agreement. Patient's specificities and economical aspects must also be considered. Procedures and follow-up must be realized by referents actors.

CONCLUSION: Indication, procedure and follow-up of ablative therapies in prostate cancer require specific modalities. They must be respected in order to optimize the results and to obtain a precise and objective evaluation for defining future indications.